Physician profile
Kenneth Paris
NPI 1629183157
$150,252.61
in general payments reported to CMS, 2019-2025
18 companies · $5,255 in 2025
The $5,255 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $18K · 2021: $12K · 2022: $22K · 2023: $43K · 2024: $38K · 2025: $5,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $36K · Travel and Lodging: $7,540 · Food and Beverage: $3,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,366.25 |
| Consulting Fee | $36,296.12 |
| Travel and Lodging | $7,540.26 |
| Food and Beverage | $3,816.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $113,239.64 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Biocryst US Sales Co., LLC | $8,047.62 | 2024-2025 | Orladeyo |
| Shire North American Group INC | $7,180.24 | 2019 | |
| Grifols USA, LLC | $6,183.87 | 2019-2024 | Xembify |
| Glaxosmithkline, LLC. | $6,048.81 | 2019-2023 | Nucala |
| Biocryst Pharmaceuticals, INC. | $3,648.52 | 2019-2024 | |
| Csl Behring | $3,097.34 | 2019-2025 | Hizentra, Privigen |
| Pfizer INC. | $925.00 | 2022 | |
| Genzyme Corporation | $470.89 | 2020-2025 | |
| Amgen INC. | $424.22 | 2023-2025 | Actimmune, Tezspire |
| Grifols Shared Services North America, INC. | $327.22 | 2019-2024 | Xembify |
| Astrazeneca Pharmaceuticals LP | $249.29 | 2019-2025 | Tezspire, Fasenra |
| Theratechnologies INC. | $97.11 | 2023 | Egrifta Sv |
| Regeneron Healthcare Solutions, INC. | $91.13 | 2023-2025 | Dupixent |
| Horizon Therapeutics Plc | $83.42 | 2019-2023 | Actimmune |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $71.87 | 2025 | |
| Sumitomo Pharma America, INC. | $50.00 | 2023 | Rethymic |
| Galderma Laboratories, L.P. | $16.42 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Paris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.